Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Tumor Immune Microenvironment and Response to Neoadjuvant Chemotherapy in Hormone Receptor/HER2+ Early Stage Breast Cancer

Clinical Breast Cancer(2022)10.1016/j.clbc.2022.04.002Source: DataRank Database

Tumor Immune Microenvironment and Response to Neoadjuvant Chemotherapy in Hormone Receptor/HER2+ Early Stage Breast Cancer is a research paper published in Clinical Breast Cancer (2022). On theSindex it has a DataRank of 0. It has been cited 18 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access18 citations

Download PDF

Cite:

Linked data & code

doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (8 grants)Impact (FWCI 1.77)OA: greenTopics (61)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (16)

Kathleen Fenn ORCID,Matthew Kearney ORCID,Qi Wang ORCID,Hua Guo ORCID,Douglas K. Marks ORCID

Live enrichment

PubMed:35610143 PMC:PMC10266131 OpenAlex:https://openalex.org/W4224041510

National Center for Advancing Translational Sciences

Grant: KL2 TR000081

NCI NIH HHS

Grant: P30 CA008748

NCATS NIH HHS

Grant: UL1 TR000040

National Institutes of Health

Grant: 8KL2TR000081-07

Clinical and Translational Science Award

Bristol-Myers Squibb

Eisai

Merck

National Institutes of Health

FWCI

1.77

Citation Percentile

0.9%

Citation Trend

2022

2023

2024

2025

2026

greenLicense: Elsevier TDM

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC10266131/pdf/nihms-1883654.pdf

publisherhttps://api.elsevier.com/content/article/PII:S1526820922000714?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1526820922000714?httpAccept=text/plain

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/10266131

Fields of Study

Cancer Immunotherapy and BiomarkersBreast Cancer Treatment StudiesImmunotherapy and Immune Responses03 medical and health sciences0302 clinical medicineAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBreast NeoplasmsFemaleForkhead Transcription FactorsHormonesHumansLymphocytes, Tumor-InfiltratingNeoadjuvant TherapyPrognosisErb-b2 Receptor Tyrosine KinasesTumor Microenvironment

MeSH Terms

Antineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsFemaleHormonesHumansPrognosisBiomarkers, TumorLymphocytes, Tumor-InfiltratingReceptor, ErbB-2Erb-b2 Receptor Tyrosine KinasesNeoadjuvant TherapyForkhead Transcription FactorsTumor Microenvironment

Keywords

Breast cancerMedicineTumor microenvironmentStromal cellNeoadjuvant therapyFOXP3Immune systemOncologyCD8Hormonal therapyHormone receptorCancerTumor-infiltrating lymphocytesCancer researchInternal medicinePathologyImmunologyTumor infiltrating lymphocytesGene Expression SignaturesHer2 PositiveQuantitative Multiplex ImmunofluorescenceBreast NeoplasmsForkhead Transcription FactorsPrognosisErb-b2 Receptor Tyrosine KinasesHormonesLymphocytes, Tumor-InfiltratingAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorHumansFemale

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

Tumor Immune Microenvironment and Response to Neoadjuvant Chemotherapy in Hormone Receptor/HER2+ Early Stage Breast Cancer

FAIR Checklist

Authors (16)

Funding (8 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)